High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 35192196.
- Also identified by DOI 10.1111/bjd.21066.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this case series, ustekinumab therapy demonstrated efficacy in some patients with severe hidradenitis suppurativa previously treated with adalimumab and/or infliximab. Larger prospective studies are needed to evaluate ustekinumab as a treatment option for recalcitrant hidradenitis suppurativa.
Medical subject headings
- Dermatologic Agents
- Hidradenitis Suppurativa